Cargando…

Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH

It has been postulated that inflammasomes, in particular the NLRP3 (NLR family pyrin domain containing 3) inflammasome, mediate the necroinflammation and fibrosis that characterize nonalcoholic steatohepatitis (NASH) by engaging innate immune responses. We aimed to investigate the impact of genetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ioannou, George N., Horn, Christian L., Kothari, Vishal, Yeh, Matthew M., Shyu, Irene, Lee, Sum P., Savard, Christopher E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944495/ https://www.ncbi.nlm.nih.gov/pubmed/36641116 http://dx.doi.org/10.1016/j.jlr.2023.100330

Ejemplares similares

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

sTREM2 is a plasma biomarker for human NASH and promotes hepatocyte lipid accumulation
por: Kothari, Vishal, et al.
Publicado: (2023)

Genetic Deletion or Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Cardiac Ischemia/Reperfusion Injury by Attenuating NLRP3 Inflammasome Activation
por: Darwesh, Ahmed M., et al.
Publicado: (2019)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
por: Li, Cong, et al.
Publicado: (2022)

Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase
por: Shi, Wei, et al.
Publicado: (2023)

Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model
por: Vargas-Pozada, Eduardo E., et al.
Publicado: (2022)

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
por: Zhan, Xiaoyan, et al.
Publicado: (2023)

Curcumin Ameliorates Diabetic Nephropathy by Suppressing NLRP3 Inflammasome Signaling
por: Lu, Miaomiao, et al.
Publicado: (2017)

Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation
por: Yu, Xianjun, et al.
Publicado: (2017)

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
por: Xu, Congfei, et al.
Publicado: (2018)

NLRP6 Inflammasome Ameliorates Brain Injury after Intracerebral Hemorrhage
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Ketogenic diet ameliorates inflammation by inhibiting the NLRP3 inflammasome in osteoarthritis
por: Kong, Ganggang, et al.
Publicado: (2022)

Ruscogenin Ameliorated Sjögren's Syndrome by Inhibiting NLRP3 Inflammasome Activation
por: He, Jing, et al.
Publicado: (2022)

Glibenclamide ameliorates the disrupted blood–brain barrier in experimental intracerebral hemorrhage by inhibiting the activation of NLRP3 inflammasome
por: Xu, Fulin, et al.
Publicado: (2019)

OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
por: Sánchez-Fernández, Alba, et al.
Publicado: (2019)

Therapeutic Potential of Pharmacological Targeting NLRP3 Inflammasome Complex in Cancer
por: Tezcan, Gulcin, et al.
Publicado: (2021)

Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2021)

NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors
por: Xu, Yi, et al.
Publicado: (2023)

Pharmacological intervention of curcumin via the NLRP3 inflammasome in ischemic stroke
por: Du, Xiaoxue, et al.
Publicado: (2023)

Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis
por: Cai, Yawen, et al.
Publicado: (2022)

Flavonoids Ameliorate Stress-Induced Depression by Preventing NLRP3 Inflammasome Priming
por: Pasinetti, Giulio
Publicado: (2022)

Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice
por: Bellut, Maximilian, et al.
Publicado: (2023)

The Impact of Melatonin Supplementation and NLRP3 Inflammasome Deletion on Age-Accompanied Cardiac Damage
por: Sayed, Ramy K. A., et al.
Publicado: (2021)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically
por: González-Moro, Ainara, et al.
Publicado: (2022)

Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines
por: Dashdorj, Amarjargal, et al.
Publicado: (2013)

A novel danshensu derivative ameliorates experimental colitis by modulating NADPH oxidase 4‐dependent NLRP3 inflammasome activation
por: Pan, Li‐Long, et al.
Publicado: (2020)

Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation
por: Mavrogiannis, Emmanouil, et al.
Publicado: (2022)

Inhibition of NLRP3 Inflammasome Ameliorates Cerebral Ischemia-Reperfusion Injury in Diabetic Mice
por: Hong, Pu, et al.
Publicado: (2018)

Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition
por: Ma, Sai, et al.
Publicado: (2018)

Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice
por: Zhao, Jingfei, et al.
Publicado: (2020)

Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice
por: Yu, Yongxiang, et al.
Publicado: (2021)

Biejiajian Pill Ameliorates Diabetes-Associated Atherosclerosis through Inhibition of the NLRP3 Inflammasome
por: Fu, Yu, et al.
Publicado: (2022)

Puerarin ameliorates acute lung injury by modulating NLRP3 inflammasome-induced pyroptosis
por: Cai, Dasheng, et al.
Publicado: (2022)

Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment
por: Liu, Tingting, et al.
Publicado: (2022)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pu0d6ugoa6q41gm5mjf672qp98